Celldex
Therapeutics Inc. (Nasdaq: CLDX) reported positive interim data from a Phase 2
study of rindopepimut in treating patients with EGFRvIII-positive
glioblastoma sending the stock price soaring $4.74 to $18.90.
Celldex reports positive interim data
November 17, 2014 at 05:00 AM EST
